MetaVia announces Dr. Sarah Browne as Chief Medical Officer to advance its portfolio of cardiometabolic drugs, including Phase 3 candidate DA-1726, stimulating investor interest in the company's pipeline potential.
MetaVia announces Dr. Sarah Browne as Chief Medical Officer to advance its portfolio of cardiometabolic drugs, including Phase 3 candidate DA-1726, stimulating investor interest in the company's pipeline potential.